Macular vitelliform lesion in desferrioxamine-related retinopathy
- 9 June 2010
- journal article
- case report
- Published by Springer Nature in Documenta Ophthalmologica
- Vol. 121 (2) , 161-166
Abstract
To report a case of a macular vitelliform lesion associated with desferrioxamine treatment. Ocular, electrophysiological, psychophysical, perimetric, fluorescein angiographic, fundus autofluorescence, and spectral-domain OCT examinations were obtained on a 45-year-old Caucasian woman with thalassemia major treated with blood transfusions and desferrioxamine. The patient was observed to have a vitelliform macular lesion in the right eye with a hypopigmented macular lesion and retinal pigment mottling in the left. At the most recent follow-up visit, best-corrected visual acuity was 20/70 in the right eye and 20/25 in left. Full-field electroretinogram (ERG) testing showed normal cone and rod responses. Mild localized elevations of rod psychophysical thresholds were found. A vitelliform macular lesion can develop in patients treated with desferrioxamine. Some such patients may not show diffuse photoreceptor cell functional loss as determined by electrophysiological testing.Keywords
This publication has 19 references indexed in Scilit:
- ISCEV Standard for full-field clinical electroretinography (2008 update)Documenta Ophthalmologica, 2008
- Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicityAmerican Journal of Hematology, 2003
- The expanded clinical spectrum of deferoxamine retinopathy11The authors have no commercial or proprietary interest in any of the materials noted in this article.Ophthalmology, 2002
- Vision and hearing during deferoxamine therapyThe Journal of Pediatrics, 1990
- Ocular and Auditory Toxicity in Hemodialyzed Patients Receiving DesferrioxamineNephron, 1990
- Ocular toxicity of desferrioxamine--an example of copper promoted auto-oxidative damage?British Journal of Ophthalmology, 1989
- Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia.Archives of Disease in Childhood, 1988
- Ocular changes in patients undergoing long-term desferrioxamine treatment.British Journal of Ophthalmology, 1984
- Deferoxamine (Desferal®)-induced Toxic Retinal Pigmentary Degeneration and Presumed Optic NeuropathyOphthalmology, 1984
- OCULAR TOXICITY OF HIGH-DOSE INTRAVENOUS DESFERRIOXAMINEThe Lancet, 1983